<i>TP53</i> DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer

<i>TP53</i> DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer

(1) Background: Bevacizumab-based regimens are a standard treatment for metastatic colorectal cancer (mCRC) patients, however meaningful clinical biomarkers for treatment benefit remain scarce. (2) Methods: Tumor samples from 36 mCRC patients treated with bevacizumab-based chemotherapy underwent com...

Full description

Bibliographic Details
Main Authors: Hung-Chih Hsu, Jeng-Fu You, Shu-Jen Chen, Hua-Chien Chen, Chien-Yuh Yeh, Wen-Sy Tsai, Hsin-Yuan Hung, Tsai-Sheng Yang, Nina Lapke, Kien Thiam Tan
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cancers
Subjects:
metastatic colorectal cancer
bevacizumab therapy
next-generation sequencing
progression-free survival
<i>TP53</i> DNA binding domain mutation
Online Access:https://www.mdpi.com/2072-6694/11/8/1079

Internet

https://www.mdpi.com/2072-6694/11/8/1079

Similar Items